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ABSTRACT
Background: The juvenile form of Huntington’s
disease (HD) is a rare disorder. There are no
population-based estimates of either its incidence or
prevalence in any population in the world. The present
study was undertaken to estimate the frequency of
juvenile HD in the UK and to examine the range of
pharmacological treatments used in its management.
Method: The records of individuals under the age of
21 who had recorded diagnoses of HD were retrieved
from the General Practice Research Database from
1990 through 2010. From these data estimates of
incidence and prevalence were made as well as the
specific treatments used in the treatment of its physical
and psychological manifestations.
Results: 12 incident and 21 prevalent patients with
juvenile HD were identified. The 21 prevalent cases
included the 12 incident cases. The minimum
population-based estimate of incidence is 0.70 (95% CI
0.36 to 1.22) per million patient-years. The minimum
estimate of prevalence is 6.77/million (95% CI 5.60 to
8.12) per million patient-years. Patients were most
frequently prescribed antidepressants, hypnotics,
antipsychotics and treatments for motor abnormalities.
Conclusions: In the UK, juvenile HD is an extremely rare
and complex disorder. The prescribing data demonstrate
that the clinical management of juvenile HD is undertaken
with no formal evidence base for the efficacy or safety of
the treatments used. Research into the safety and efficacy
of appropriate therapies is urgently required to offset the
haphazard nature of prescribing. Multinational
collaboration will be necessary to enrol sufficient
numbers. Exploratory studies, though, should begin now.
INTRODUCTION
Huntington’s disease (HD) is a progressive,
fatal neurodegenerative disorder associated
with abnormal movements, psychiatric distur-
bances and cognitive decline.1 2 HD segre-
gates as an autosomal trait located in
chromosome 4p16.3. The HD gene encodes
the huntingtin protein.2 The HD abnormal-
ity is an expanded CAG repeat on exon 1 of
the HD gene leading to the corresponding
expression of an expanded polyglutamine
repeat in the huntingtin protein. Alleles with
40 or more CAG repeats invariably give rise
to HD provided that individuals live a
normal lifespan.1
The juvenile form of HD is characterised
by an onset in childhood or adolescence.
Alleles with 60 or more CAG repeats usually
result in the juvenile HD although it may
occur in patients with less than 60 repeats In
adult HD the movement disorder is typically
chorea. In juvenile HD the movement dis-
order, rather than chorea, is primarily
tremor, bradykinesia and dystonia.3–5 In
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juvenile HD cerebellar signs, epilepsy, myoclonus and
spasticity may also occur. As in adult HD, psychiatric dis-
turbances and cognitive decline are also present4 5 but
seizures are very unusual.
Although there have been various published estimates
of the incidence and prevalence of adult HD there has
been no attempt to estimate the population-based inci-
dence, or prevalence, of the juvenile form. This study
was designed to obtain an estimate of the incidence and
prevalence of juvenile HD using the General Practice
Research Database (GPRD) as well as to examine the
range of speciﬁc treatments used in its management.
METHODS
Study design and setting
The GPRD is a computerised database containing anon-
ymised electronic patient records from UK primary care.
It covers around 6% of the UK population at any one
time and both its unique features, as well as the high
quality of the data contained within it, have been
described elsewhere.6 The database is now included
under the umbrella of the Clinical Practice Research
Datalink that brings together data from across the UK’s
National Health Service.
Participants
For the purposes of this study juvenile HD was deﬁned
as onset before the age of 21 years. The source popula-
tion was therefore all patients, under 21 years of age,
registered with general practices contributing to the
GPRD, between 1990 and 2010. Eligible cases were
deﬁned as any person, under the age of 21 years, with
one or more diagnoses of HD or Huntington’s chorea
in their medical record. The last date for each record
was the earliest of either the date of death, the date of
patients’ deregistration from the practice if still alive, the
date the patient achieved the age of 21 years, the date
the practice left the GPRD, or the end of the observa-
tion period (2010). The Read codes used to identify
cases in the database were F134.00 (Huntington’s
chorea) and Eu2200 (dementia in HD).
Biases
In order to ensure that incident cases were not wrongly
identiﬁed as prevalent ones, two additional criteria for
inclusion as incident cases were applied: (1) they must
have been registered with the practice for 12 months or
longer by the date the diagnosis was recorded and (2)
they had to have had at least one other recorded contact,
with the practice, during the preceding 12-month period.
Prescription data
The medicines prescribed for incident and prevalent
patients were also retrieved from the GPRD. Medications
commonly prescribed for children and adolescents, and
not speciﬁc for those with juvenile HD (including anti-
biotics, antifungal agents, emollients and routine
vaccinations) were not examined further. Speciﬁc treat-
ments for the symptoms and signs of juvenile HD were
analysed in detail. Those treatments prescribed more
than twice for a particular patient were categorised as
‘regular’ treatments.
Statistical methods
Incidence was calculated from the numbers of incident
cases (as deﬁned above under biases), within 5-year age-
bands, in relation to the total number of patient-years
within the same age-band. Prevalence was calculated, for
each year during the study period (1990–2010), from the
numbers of patients with recorded juvenile HD divided
by the total numbers of patients aged less than 21 years
during that year. For estimates of both incidence and
prevalence binomial 95% CIs were calculated.
RESULTS
Main findings: incidence
There were 12 records (4 females, 8 males) of patients
fulﬁlling the criteria for inclusion as incident cases of
juvenile HD. Their ages, at diagnosis, ranged from 5 to
20 years (median 15 years). The overall incidence was
0.70 (95% CI 0.36 to 1.22) per million patient-years.
The estimates of incidence in 5 year age-bands (table 1)
ranged from 0 (95% CI 0 to 1.1) per million patient-
years at age 0–4 years, to 1.26 (95% CI 0.46 to 2.74) per
million patient-years at aged 15–20 years.
Eight of the 12 incident cases had records of potential
prodromal diagnoses, suggestive of juvenile HD, up to
3 years before a formal diagnosis of HD was entered into
their records. These included sleep disorders (3 cases), psy-
chiatric referrals (2 cases), movement disorders (2 cases)
and referral for genetic counselling (1 case). The remain-
ing cases had no obvious prodromal reported diagnoses.
Main findings: prevalence
There were 21 records (8 females, 13 males) of indivi-
duals contributing to the database, aged less than
21 years, with a diagnosis of HD. They provided a total
of 116 patient years within the database. These 21 preva-
lent cases included the 12 incident cases. The average
annual prevalence of juvenile HD, between 1990 and
2010, was 6.77/million (95% CI 5.60 to 8.12/million)
but ﬂuctuated year by year (table 2).
Table 1 Incidence estimates of juvenile Huntington’s
disease in the UK
Age
group
(years)
Incident
cases
Population
(patient
years)
Incidence per million
patient-years
(95% CI)
0–4 0 4097551 0 (0 to 1.1)
5–9 3 4156414 0.7 (0.2 to 2.1)
10–14 3 4115431 0.7 (0.2 to 2.1)
15–20 6 4762455 1.3 (0.5 to 2.7)
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Prescription data
Prescription data for the treatment relevant to the symp-
toms and signs of juvenile HD among prevalent cases
are summarised in table 3. One patient had no prescrip-
tions recorded during the observation period and six
were prescribed products for intercurrrent conditions
(mainly antimicrobial agents, oral contraceptives, anti-
asthma products and vaccines) which were assumed to
be unrelated to HD.
Fourteen patients were prescribed regular treatments
apparently for the speciﬁc management of their HD
symptomatology. Simultaneous prescriptions of more
than one therapeutic category were common. The pro-
ducts most commonly prescribed included antidepres-
sants (particularly ﬂuoxetine and citalopram), a wide
variety of treatments for motor disorders (including
baclofen, levodopa, amantidine and tetrabenazine), hyp-
notics, antipsychotics (risperidone and olanzepine) and
anticonvulsants (especially valproate and clobazam).
Because of the small number of patients it would be
inappropriate to use these data to infer the relative fre-
quencies of the phenotypic variations, in the clinical
manifestations of juvenile HD. Nevertheless, the data
correspond—at least qualitatively—to the phenotypic
patterns observed in reports of juvenile HD.5
DISCUSSION
There have been a number of population-based studies
of the prevalence of HD that have provided information
about the proportion of cases with the juvenile form of
the condition.7 8 It is not possible to infer from these
reports the prevalence of juvenile HD, because none
provide estimates of the relevant population under
21 years of age. The estimates of incidence and preva-
lence of juvenile HD reported here are, therefore, the
ﬁrst to provide population-based epidemiological data
on the frequency of this condition either in the UK or
worldwide. The apparent increase in the incidence of
juvenile HD with age, in table 1, is intuitively appropri-
ate. However, because of the small numbers involved it is
impossible to be certain.
Our estimates of both the incidence and prevalence of
juvenile HD, almost certainly underestimate the true fre-
quency of juvenile HD. First, it is possible that some
general practitioners chose not to record their patients’
HD diagnoses for reasons of conﬁdentiality. Second, the
dates of onset of past diagnoses are not always reliably
recorded. Past diagnoses may be recorded either
without a date or as occurring at the date of registration.
These cases were excluded from our analysis of inci-
dence. Third, we report the dates of recorded diagnoses.
Possibly, some patients diagnosed in adulthood began
showing symptoms in childhood or adolescence. These
cases were also excluded. Finally, the strict criteria we
applied in deﬁning incident cases might have resulted
in omitting some who should have been assigned to this
category. However, only two prevalent cases were
excluded as incident cases (one aged 12 years and the
other aged 19 years) because their records failed to
include any other contact with the practice in the
12 months prior to the entry of a diagnosis of HD.
Extrapolated to the entire UK population our results
suggest that at a minimum, there are 100 children and
adolescents living with juvenile HD. This does not of
course include patients, over the age of 20 years, during
the period of the study, who were originally diagnosed as
juvenile HD. Again, extrapolating to the UK as a whole,
we estimate that 10 new cases are diagnosed annually.
Most of the potential prodromal diagnoses, reported
for incident cases, were typical of the clinical features of
Table 3 Prescriptions for the specific management of
patients with juvenile Huntington’s disease
Therapeutic category
Number of patients having
products prescribed
(regular prescriptions*)
Antidepressants 8 (6)
Motor abnormalities 7 (5)
Hypnotics 7 (3)
Antipsychotics 6 (3)
Anticonvulsants 5 (5)
Anxiolytics 3 (0)
Food supplements 2 (2)
Wound dressings 2 (2)
*Regular prescriptions are those prescribed to a particular patient
more than twice.
Table 2 Prevalence estimates of juvenile Huntington’s
disease in the UK
Year
Prevalent
cases
Numbers in
GPRD aged
less than
21 years
Prevalence per
million (95% CI)
1990 1 248518 4.0 (0.1 to 22.4)
1991 1 304836 3.28 (0.1 to 18.3)
1992 1 350401 2.9 (0.1 to 15.9)
1993 5 376180 13.3 (4.3 to 31.0)
1994 5 406351 12.3 (4.0 to 28.7)
1995 6 434286 13.8 (5.1 to 30.1)
1996 6 524798 11.4 (4.2 to 24.9)
1997 6 605201 9.9 (3.6 to 21.6)
1998 6 708142 8.5 (3.1 to 18.4)
1999 7 850823 8.2 (3.3 to 17.0)
2000 6 946889 6.3 (2.3 to 13.8)
2001 6 1016667 5.9 (2.2 to 12.9)
2002 7 1075286 6.5 (2.6 to 13.4)
2003 8 1104342 7.2 (3.1 to 14.3)
2004 10 1133156 8.8 (4.2 to 16.2)
2005 8 1153294 6.9 (3.0 to 13.7)
2006 6 1176419 5.1 (1.9 to 11.1)
2007 7 1188555 5.9 (2.4 to 12.1)
2008 8 1184231 6.8 (2.9 to 13.3)
2009 3 1175793 2.6 (0.5 to 7.5)
2010 3 1167683 2.6 (0.5 to 7.5)
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juvenile HD, including motor disturbances and psychi-
atric problems. It is striking that three patients com-
plained of sleep disturbances. This has not previously
been reported in association with juvenile HD.
Furthermore, hypnotics were prescribed to a signiﬁcant
proportion of juvenile HD patients.
The symptomatology of juvenile HD is complex and
causes suffering in all domains of life. The range of
pharmacological products prescribed (table 3) for our
cohort of people with juvenile HD are similar to that
recently reported by Robertson et al.9 Most of the treat-
ments for the motor manifestations of juvenile HD are
those shown to be effective in Parkinson’s disease but
none have ever been formally assessed in juvenile HD.
Even though a wide range of other therapies are used,
often simultaneously, there are no studies to guide the
current trial-and-error ‘experimental’ approach to the
treatment of juvenile HD. No studies of the effectiveness
of antidepressants, antipsychotics or anticonvulsants
have ever been done to assess the effectiveness of these
treatments in juvenile HD. In particular, in view of
current anxieties about the potential hazards of using
antidepressants in children,10 clinical trials of the effect-
iveness of speciﬁc serotonin reuptake inhibitors, are
especially urgent. The present investigation also suggests
that there is a critical need to assess the comparative
effectiveness of other treatment options in juvenile HD.
Because the number of children and adolescents with
juvenile HD are small, in any one country such as the
UK, only multinational trials are likely to produce the
most rigorous answers. Small exploratory studies should
be initiated immediately to guide the design of larger
trials as well as provide some early answers.
The humane and supportive care of children and ado-
lescents with HD requires the availability of appropriate
resources to be provided by the UK’s health and social
services. These resources are complex and multidiscip-
linary. It is incumbent on those planning the provision
of such care that the needs of these young people—and
their families—are met.
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